(Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi ® (seladelpar) was associated with high and sustained rates of normalization of a key liver marker (ALP) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results